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Abstract
Background
In mid-2016, Mozambique began phased implementation of the ‘Test-and-Treat’ policy,
which enrolls HIV positive clients into antiretroviral treatment (ART) immediately regardless
of CD4 cell count or disease stage. Novel insights into barriers and facilitators to ART initia-
tion among healthy clients are needed to improve implementation of Test and Treat.
Methods and findings
A cross-sectional qualitative study was conducted across 10 health facilities in Mozam-
bique. In-depth interviews (IDIs) were conducted with HIV-positive clients (60 who initiated/
20 who did not initiate ART within Test and Treat) and 9 focus group discussion (FGDs)
were conducted with health care workers (HCWs; n = 53). Data were analyzed using deduc-
tive and inductive analysis strategies. Barriers to ART initiation included: (1) feeling ‘healthy’;
(2) not prepared to start ART for life; (3) concerns about ART side effects; (4) fear of HIV dis-
closure and discrimination; (5) poor interactions with HCWs; (6) limited privacy at health
facilities; and (7) perceptions of long wait times. Facilitators included the motivation to stay
healthy and to take care of dependents, as well as new models of ART services such as
adaptation of counseling to clients’ specific needs, efficient patient flow, and integrated HIV/
primary care services.
Conclusions
ART initiation may be difficult for healthy clients in the context of Test-and-Treat. Specific
strategies to engage this population are needed. Strategies could include targeted support
for clients, community sensitization on the benefits of early ART initiation, client-centered
PLOS ONE | https://doi.org/10.1371/journal.pone.0205919 December 26, 2018 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Nhassengo P, Cataldo F, Magac¸o A,
Hoffman RM, Nerua L, Saide M, et al. (2018)
Barriers and facilitators to the uptake of Test and
Treat in Mozambique: A qualitative study on patient
and provider perceptions. PLoS ONE 13(12):
e0205919. https://doi.org/10.1371/journal.
pone.0205919
Editor: Jonathan Garcia, Oregon State University,
UNITED STATES
Received: May 8, 2018
Accepted: October 2, 2018
Published: December 26, 2018
Copyright: © 2018 Nhassengo et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Due to the qualitative
nature of this study, the presence of sensitive
information, and the potential to identify some
participants based on their responses in the
interviews, data are not publicly available. De-
identified data may be available upon request for
researchers who meet the criteria for access to
confidential data (received a letter of human
subjects research exemption from an institutional
review board and have completed the research
ethics trainings required by their institution). All
approaches to patient care, and improved efficiency through multi-month scripting and
increased workforce.
Introduction
In 2015, the World Health Organization (WHO) announced new universal treatment guide-
lines for antiretroviral treatment (ART), which support initiation of ART for all individuals liv-
ing with HIV, independent of their immunologic or clinical status.[1] Since then, countries
throughout sub-Saharan Africa have adopted the “Universal Test-and-Treat” (Test and Treat)
strategy.[2] The strategy is expected to contribute to improved client outcomes and attaining
UNAIDS 90-90-90 treatment targets, specifically the ART coverage target.[3] Despite rapid
advances in the implementation of Test and Treat, to date, there are limited data on barriers
and facilitators to ART initiation under the new policy, particularly among non-pregnant and
non-breastfeeding populations who are, for the first time, eligible for ART initiation when
asymptomatic at the time of HIV diagnosis (i.e., healthy clients). Limited research has been
conducted in Mozambique to understand barriers and facilitators to ART initiation.[4–11]
Previous research in sub-Saharan Africa identified multiple barriers to ART initiation for
adults eligible for treatment based on clinical criteria, such as CD4 count or WHO stage.[12–
15] Dominant barriers include: concerns related to stigma, confidentiality, and privacy whilst
accessing HIV services; negative treatment by clinical staff; conflicting demands on clients’
time; distance to the health facility; poor knowledge of ART regimens; and fear of side effects.
[15–20] Another body of literature on Option B+, whereby universal treatment is available for
all pregnant and breastfeeding women regardless of CD4 count, may provide insight on the
experiences of healthy populations. Pregnant and/or breastfeeding women eligible for treat-
ment under Option B+ report the following barriers to ART initiation: not prepared to start
lifelong treatment; fearing partner response to a positive status; fear of disclosure; and fear of
side effects.[21–23] While these findings provide insight to healthy populations, they may not
apply to healthy, non-pregnant clients. Non-pregnant/breastfeeding HIV positive clients who
feel healthy may not perceive or understand the need to start ART immediately; they also may
not have the additional motivation of preventing mother-to-child-transmission experienced
by pregnant/breastfeeding women.
We performed a qualitative study to assess barriers and facilitators to ART initiation among
healthy clients eligible for ART under the new Test and Treat policy in Mozambique. The
study includes perspectives from both providers and clients. This is one of the first studies in
sub-Saharan Africa to explore barriers to ART uptake among asymptomatic non-pregnant/
breastfeeding populations in the context of Test and Treat.
Methods
Setting
In Mozambique, a country of 27 million people, an estimated 13.2% of adults (aged 15 to 49
years) are living with HIV.[24] To date, approximately 56% of clients eligible for ART have ini-
tiated treatment.[25] In August 2016 Mozambique began a phased implementation of Test
and Treat, known locally as Testar e Iniciar (“Test and Start”), which intends to enroll all HIV
positive clients into care and start ART within fifteen days of a positive HIV diagnosis.
Mozambique has taken a human rights approach to linkage to care. While linkage is actively
facilitated, clients who test HIV positive and are not ready to initiate ART can remain
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anonymous, allowing positive clients to ‘opt-in’ by presenting themselves for ART rather than
being actively traced. Clients may enroll into ART program to receive support for their HIV
positive status, such as counseling and support groups, and decline treatment initiation.
Study sites
Study participants were recruited from 10 health facilities located in urban and peri-urban
areas across 4 provinces in the Northern, Central, and Southern regions of the country. Sites
were eligible if they had a medium to large ART cohort size (defined as> 2000 patients cur-
rently on ART) and an active electronic patients tracking system (EPTS) in place 12 months
before the Test and Treat policy. All included sites began the Test and Treat rollout in August
2016. Provincial, central and private hospitals were excluded because of their non-representa-
tive characteristics of the primary level of care and HIV services (in relation to staffing, service
provision and levels of technical expertise). Since multiple sites from the same province met
inclusion criteria, we randomly selected a geographical region within each province (see Fig
1). Eligible sites from the same geographical region were grouped together and numbered.
Through consecutive randomization processes, 12 potential sites were identified. Two sites
were excluded due to concerns around accessibility and low number of new enrollees during
the study period.
Study participants and data collection
Focus group discussions (FGDs) (n = 9) were conducted with health care workers (HCWs) at
study sites. A total of 53 HCWs participated. Four of the 9 FGDs were conducted with health
care providers who directly provided ART care (doctors, clinical officers, nurses, maternal and
child health nurses, laboratory, and pharmacy staff). The other 5 FGDs were conducted with
supporting staff who were engaged in HIV care services (HIV counselors, community health
workers called “Agente Polivalente Elementary”, and trained peer educators). HCWs were eligi-
ble for the study if they had been actively engaged in HIV/ART services for at least one year.
Discussions focused on HCW observations and perceptions of barriers and facilitators to ART
initiation under Test and Treat. We specifically asked if HCWs believed there barriers and
facilitators differed for healthy clients under the new policy as compared to clients eligible for
ART under older eligibility criteria that relied on CD4 count and/or clinical stage.
In-depth interviews (IDIs) were conducted with 80 people (43 females and 37 males). Eligi-
bility criteria included: (1) non-pregnant/breastfeeding; (2) adult (15 years of age and older);
(3) newly diagnosed HIV-positive between August 2016 –February 2017, after the implemen-
tation of Test and Treat; and (4) asymptomatic at the time of diagnosis (i.e., not requiring ART
initiation due to acute illness or opportunistic infection. We enrolled two groups of individuals
who received an HIV positive test under Test and Treat and categorized them based on
whether they initiated ART within 14 days of diagnosis (based on government guidelines rec-
ommending initiation within a 14 day window): (1) those who initiated ART within 14 days
after receiving an HIV positive diagnosis (n = 60) (‘initiates’) and (2) those who were enrolled
into care but did not initiate ART within 15 days (n = 20) (‘non-initiates’). New ART initiates
were recruited after ART uptake and counseling sessions. Non-initiates were recruited from
HIV service clinics that provide support for people living with HIV or from referrals through
community health workers. All clients were screened through the standard study screening
procedure (see Fig 2). The interview guide was informed by existing literature [10, 11, 15, 18,
19] and the socioecological model that provides a platform to examine the multiple and
dynamic levels within individuals, communities, and society that influence ART initiation
[26]. The interview guide included four domains: sociodemographic data; experience with
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Fig 1. Map of study sites.
https://doi.org/10.1371/journal.pone.0205919.g001
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HIV diagnosis and HIV services at their local health facility; perceptions of ART; and per-
ceived barriers and facilitators to their initiation of ART, drawing specifically on barriers and
facilitators at multiple levels of the socioecological model.
All data were collected by trained, local research assistants who were experienced in qualita-
tive research in the field of HIV and health services. Data collection tools were developed
based on the outcomes of similar studies carried out in the region and open-ended questions
were predominant. Probing technique was applied for following up and clarification as
needed. In-depth interviews lasted approximately 40 minutes while focus group discussions
lasted approximately 80 minutes.
Analysis
All FGDs and IDIs were recorded and transcribed verbatim in Portuguese and translated into
English. Analytical themes and codes were derived from the study objectives around facilita-
tors and barriers of ART uptake and retention in care.[27] Transcripts were analyzed using
NVivo11 software to extract and sort interview text into single-file statements with the same
code from all interviews.[28] Deductive and inductive coding was conducted independently
by PN, LN, MS, FC, and AM.[29] Codes were compared for consistency and all discrepancies
resolved across the five investigators.
Ethical considerations
This study was approved by the Institutional Ethics Committee of the Instituto Nacional de
Sau´de (National Institute of Health) in Maputo, Mozambique (ref. no. 025/CIBS-INS/2017)
and the Institutional Review Board at the University of California, Los Angeles, USA (approval
no. 17–001182). Based on Mozambique law, no parent/guardian consent was needed for par-
ticipants. This was approved by local ethics review committees. Further, while our eligibility
criteria was 15 years of age or older, we did not enroll anyone below 18 years (based on who
Fig 2. Study recruitment process and screening.
https://doi.org/10.1371/journal.pone.0205919.g002
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presented as a new HIV positive client during the study period). The study was performed in
accordance with the study protocol, the Declaration of Helsinki (October 2013) and the WHO
Handbook for Good Clinical Research Practice (July 2002). Participants were not paid for
their participation in the study. All study participants completed a written informed consent
prior to enrollment in the study. Thumb prints were taken for respondents who were unable
to write.
Results
Socio demographic data
Sociodemographic data of HIV-infected participants in IDIs are described in Table 1. Respon-
dents included 43 females and 37 males. Median age was 37 (IQR, 28–43). Thirty-seven
Table 1. Socio-demographic data–individuals living with HIV.
Initiates
(n = 60)
Non-initiates
(n = 20)
Total (N = 80)
Median age (IQR) 37 38 37 (28–43)
Male
Female
24 (40%)
36 (60%)
13 (65%)
7 (35%)
37 (46%)
43 (54%)
Mean n. of children (Range) 2 (0–2) 1 (0–1) 1 (0–2)
Education level completed
Primary 27 (45%) 7 (35%) 34 (42.5%)
Secondary/Higher 22 (37%) 11 (55%) 33 (41%)
No education 11 (13%) 2 (10%) 13 (16%)
Occupation
Formal/Informal work 52 (87%) 15 (75%) 67 (84%)
No work/Student 8 (13%) 5 (25%) 13 (16%)
Time knowing HIV+ serostatus
1–3 Months 32 9 41
3–6 Months 28 11 39
Average travel time to clinic
< 30 Min 30 11 41
30 Min-2h 25 9 34
> 2h 5 0 5
Self-assessment of health status
Very good/Excellent 33 (55%) 8 (40%) 41 (51%)
Good 26 (43%) 10 (50%) 36 (45%)
Poor 1 (1%) 2 (10%) 3 (3%)
Disclosed to partner 36 (60%) 10 (50%) 46 (57%)
Know partner status 34 (56%) 10 (50%) 44 (55%)
Partner status
HIV + 25 (42%) 9 (45%) 34 (42.5%)
HIV - 9 (15%) 1 (5%) 10 (12.5%)
Refuse to disclose 4 (7%) 1 (5%) 5 (6%)
Do not know 22 (36%) 9 (45%) 31 (39%)
Total informants by Province
Maputo 11 5 16
Gaza 20 3 23
Zambézia 13 3 16
Nampula 16 9 25
https://doi.org/10.1371/journal.pone.0205919.t001
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respondents had known their HIV status for 1–3 months, and 43 for more than 3 months.
Education levels varied, with most completing at least primary school. Most interviewees
received some income from formal or informal work including subsistence agriculture (83%).
Average travel time to health facilities ranged from 30 minutes to 2 hours, with about half of
the interviewees (51%) requiring less than 30 minutes to reach a health facility. More than half
of the respondents (57%) had disclosed their HIV status to their spouse or partner, and more
than half stated that they knew their partner’s serostatus (55%).
Sociodemographic data of providers participating in FGDs are described in Table 2.
Respondents included 20 females and 33 males. Median age was 36 years (IQR 28–40) and
median years working in HIV services was 4 years (IQR 2–7).
Barriers to initiating ART
Both HCWs and clients identified a range of barriers to ART initiation.
Client acceptance of HIV status and ART. Feeling ‘healthy’ was described by health pro-
viders (8/9 FGDs) and some of the clients (7/80) as one of the main reasons for not believing a
positive test result. One female client who refused to start ART described her “disbelief” at
receiving a positive HIV diagnosis despite feeling well: “I didn't believe it [HIV test result], I’m
fine, I don’t feel anything” (Female client, Non-initiate, Maputo). Another client stated: “I
thought they [HCWs] were playing with me” (Male client, Non-initiate, Gaza).
Feeling ‘healthy’ and being asymptomatic was also cited by most providers (9/9 FGDs), and
some clients (7/80), as an important barrier to starting ART. One of the HCWs in Nampula
explained that “patients say: I am not yet prepared because I am not yet sick, I am not yet sick, I
cannot accept to start with the treatment today” (female HCW, support staff, Nampula).
Another HCW described:
“A person, as long as he has no symptoms, having been tested and diagnosed, to say he has to
start ART does not seem to be a reality; the person wants to believe that he is ill when he is in bed,
while he is still healthy does not feel like he is really sick” (male HCW, support staff, Gaza).
Lack of information about ART was cited by both health providers and clients as an impor-
tant barrier to starting ART. Some clients complained about having to start medication with-
out fully understanding adherence requirements and how long they needed to take treatment.
Others explained they were not aware of the new Test and Treat policy and felt confused and
unprepared to start treatment immediately after a positive test.
“They [HCWs] were not very explicit, they didn’t explain much. They just started the process
and said tomorrow you should come back to pick up these medicines, I didn’t know what med-
icines they were talking about.” (Male client, Non-initiate, Nampula)
Table 2. Socio-demographic data–Health care providers participating in FGDs.
Maputo
(n = 12)
Gaza
(n = 14)
Zambe´zia
(n = 8)
Nampula
(n = 19)
Total
(N = 53)
Median age (IQR) 29 (28–39) 36 (29–39) 36 (26–40) 36 (30–44) 36 (28–40)
Male
Female
3
9
8
6
8
0
14
5
33 (62%)
20 (38%)
Occupation
Health facility clinical staff (doctor, clinical officer, nurse, pharmacist, lab technician, etc.) 5 8 4 9 26
Supporting staff (counselors, community health workers) 7 6 4 10 27
Median years working in HIV services (IQR) 2 (1–5) 4.5 (4–7) 3 (3–9) 3 (1–6) 4 (2–7)
https://doi.org/10.1371/journal.pone.0205919.t002
Barriers and facilitators to uptake of Test and Treat in Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0205919 December 26, 2018 7 / 17
“Every patient resists” added one of the HCWs in Zambe´zia, who explained that clients may
not understand the reason for starting ART and the necessity to be on any treatment. Another
HCW described the difficulties in starting ART immediately after the HIV test:
“It is hard for them [clients] to suddenly start the treatment immediately after the results,
some who are supposed to benefit from this treatment may not understand [. . .] for some peo-
ple it is so sudden and immediate” “Some people when they are tested are very skeptical to
start on the very same day” (male HCW, support staff, Gaza).
Several clients (26/80) expressed being reluctant to start ART ‘for life’. One of the women in
Gaza said: “pills for the rest of life is worrying” (Female client, Initiate, Gaza). One woman in
Maputo who refused to start ART described the challenge of embarking on lifelong therapy:
“I will have to take pills forever. . . Tablets forever, my God I never thought that would happen
to me, it’s unbearable to take pills the whole life. [. . .] taking pills for life every day is compli-
cated, very complicated” (Female client, Non-initiate, Maputo).
Perceived side effects. Most clients (59/80) reported that feeling dizzy and unwell could
lead them to stop taking ART: “They [ARVs] torture me, I feel bad when I take more” said a
woman who had recently initiated ART in Gaza (Female client, Initiate, Gaza). Another
woman attests to the personal challenges of starting ART: “on the first day, the reaction is very
strong and you can even quit if you are not strong and determined” (Female client, Initiate,
Nampula).
Concern about side effects was also cited as a key barrier during all discussions with HCWs,
who described their clients’ fear of possible harmful reactions:
“She [patient] was doing the treatment here but had severe reactions to the drugs and her fam-
ily didn’t understand what was going on and they thought that it was witchcraft” (male
HCW, support staff, Zambe´zia).
Some health providers also pointed at widespread negative beliefs around HIV and ART,
whereas clients described ART as a poison purposefully dispensed by HCWs. One provider
described an interaction with a client who was trying to decide to whether to take treatment or
not:
“[the patient said]: ‘My mother said don’t take it [ART]. Let’s do the family treatment [home-
made herbal medication] because it [ART] will kill you, those people [HCWs] want to kill
you’” (female HCW, clinical staff, Nampula).
Disclosure and partner involvement. Health providers and clients described the chal-
lenge of disclosure for individuals who recently tested HIV positive: “I do not trust other peo-
ple”, said one female client who initiated treatment in Gaza. Fear of discrimination, being
stigmatized, and lack of trust towards sexual partners and health providers were cited by the
majority of clients (59/80) as the main reason for not disclosing their serostatus to other indi-
viduals, including family members, friends, neighbors and the larger community; “When you
tell them [other individuals], they start to discriminate and stigmatize you, saying you are taking
antiretrovirals” (Female client, Initiate, Gaza).
One of the HCWs described their clients’ fear of disclosing in relation to the pervasive
stigma around HIV transmission:
Barriers and facilitators to uptake of Test and Treat in Mozambique
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“[. . .] what comes to their [clients’] mind is that being HIV positive is equal to having had
promiscuous conduct, bad conduct that the society doesn’t approve of” (male HCW, support
staff, Gaza).
HCWs (7/9 FGDs) indicated that some of the women who refused to start ART needed to
seek consent from their partner in order to start treatment. The low level of disclosure within
couples limited partner involvement. Several women feared that disclosing their serostatus or
openly discussing ART initiation with their partner would negatively impact their relationship
and result in rejection from their partner.
“Wives do not reveal [their HIV status] because they fear that the partner can beat them or
even get divorced because nowadays when the men know about it, they abandon the family”
(female, support staff, Zambe´zia).
One of the women who initiated ART in Gaza described the changes in her relationship
after sharing that she is living with HIV: “I realized that nothing was worthwhile looking at the
way he [partner] started talking to me. [. . .] He stopped treating me like a lady and things got
worse day in and day out” (Female client, Initiate, Gaza).
In Maputo, one of the women interviewed who refused to start ART narrated some of her
challenges in sharing her serostatus with her partner:
“I left [the facility] with the determination that I will tell him [partner] that [I am HIV posi-
tive] but when I arrived I didn’t have the courage [. . .] He will put the blame on me. [. . .] I
really want to [start ART] but I cannot start the treatment without my partner I live with.
Imagine if I start the treatment I have to take pills where am I going to hide the pills? In our
house, there is no place to hide. [. . .] I don’t want to start treatment alone [. . .] it’s as if I were
betraying him. [. . .] The biggest cause for me not to start treatment is my partner, he doesn’t
know [that I am living with HIV]; I don’t know how to tell him. (Female client, non-initiate,
Maputo)
Interactions with providers and privacy at health facilities. Some HIV-infected clients
(30/80) described negative interactions with HCWs. Clients attributed self-transfers to other
health facilities or the desire to stop ART to the perceived negative attitudes of HCWs. Some
of the clients (15/60) who had recently initiated ART perceived mistreatment by HCWs as hav-
ing a negative impact on every aspect of their clinical visits:
“They [doctors and nurses] treat us as if we are mad people. And most of the time people who
are infected tend to lose their hope in taking their life forward” (Female client, Initiate,
Maputo).
Due to limited privacy at health facilities, clients who felt healthy tended to avoid ART clin-
ics because they were concerned about being seen by relatives, friends, or neighbors. HCWs
(9/9 FGDs) reported that lack of privacy at health facilities hinders ART uptake and retention
in care. Some clients (27/80) also raised privacy as a barrier, some traveling long distances to
seek HIV care where minimum privacy could be ensured; HCWs indicated that clients who
travel long distances for HIV care are more likely to default due to limited transport money
and other expenses related to accessing care. One of the women in Gaza mentioned that “there
is no privacy, even when they [HCWs] give a prescription, because of the call [in public], people
know that so-and-so comes to get pills [ART]” (Female client, Initiate, Gaza). Some initial HIV
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counseling sessions for newly diagnosed individuals are set up as ‘group counseling’, and cli-
ents reported this as an additional deterrent due to lack of privacy and confidentiality.
Long wait times. The perception of the time required for HIV services negatively
impacted clients’ ability to initiate and continue ART, particularly for clients who fear disclo-
sure or fear to lose their job for absenteeism. One male client who refused to initiate said: “This
[wait time] makes it a bit difficult because I live based on small business, if I’m here for 30 min-
utes, this is wasting my time” (Male client, Non-initiate, Gaza).
One of the HCWs raised that it may seem impossible for some clients to take time off to
attend monthly clinic visits:
“The person [client] says [. . .] I cannot come to the hospital because my boss will not let me if
I tell him that I'm going to the hospital every month, I'm going to lose my job” (female HCW,
clinical staff, FGD).
HCWs (6/9 FGDs) also mentioned that the implementation of Test and Treat is causing a
rapid increase in the number of people coming to health facilities seeking ART services. Health
facilities are at or over capacity to deal appropriately with HIV positive clients, causing addi-
tional delays for clients needing to navigate through several cares and counseling services on
the same day.
Facilitators to initiating ART
Several facilitators were mentioned by HCWs and clients, although facilitators were men-
tioned less frequently than barriers.
Staying healthy. HCWs (8/9 FGDs) noted that women were motivated to stay healthy in
order to guarantee their children’s well-being. Most female clients (36/43) perceived ART as a
major positive determinant of their own well-being and short- as well as long-term survival.
Men also emphasized that starting ART early is a determinant of long-term survival (28/37),
helping them to be healthy and prevent opportunistic infections. A few men mentioned the
need to continue feeling healthy in order to work and make a living:
“I like what I do, so I didn’t want to have to give up because I’m sick, so the concern was to
start the treatment being healthy and to continue my work” (Male client, Initiate, Maputo).
Health service models. Health providers (9/9 FGDs) believe that new strategies for HIV
service delivery can improve ART uptake. Several new approaches to service delivery were sug-
gested by HCWs, such as the adaptation of counseling sessions to clients’ specific needs (e.g.
providing counselors with talking points that can be tailored to a client’s specific situation);
locally-designed strategies to manage client flow and reduce waiting time in light of increased
demand under Test and Treat, such as additional dedicated time for ART services and
increased workforce; gender-specific consultations for mothers, children, and men; and ‘one-
stop’ services with integrated HIV/primary care. Integrated services (HIV and primary care
services) were perceived as particularly important because the strategy could decrease wait
time and improve client privacy. In addition, HCWs believed community health-information
programs were valuable resources to increase knowledge of ART, promoting timely treatment
acceptance by clients.
Providers also noted that being professional, expressing empathy, having a caring attitude
and investing time in counseling clients, were key strategies to facilitate the initiation of ART.
Some clients (32/80) expressed feeling encouraged to continue accessing HIV services due to
the supportive attitude of some HCWs:
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“Whenever I come here I don’t find the same doctor or the same nurse, but they always receive
me well. Even when I go to get tablets, they ask me [about] sadness, they tell me not to feel
bad. They always talk to us. They care about a sick person and everyone. They do the job well”
(Female client, Initiate, Matola).
Discussion
This study is one of the first to examine barriers and facilitators for ART initiation in the con-
text of universal Test and Treat among asymptomatic non-pregnant/breastfeeding adults. We
find that already established barriers to care remain a problem for newly diagnosed clients
under the Test and Treat policy; traditional barriers continue to limit ART initiation, alongside
new barriers for healthy clients where good health makes it difficult for clients to accept a posi-
tive status or treatment initiation. Dominant barriers identified by both clients and providers
in this study include: (1) feeling healthy; (2) non-acceptance of a positive HIV status; (3) poor
knowledge about ART; (4) fear of ART side effects; and (5) fear of disclosure and lack of part-
ner involvement due to stigma and discrimination. Less dominant, but still important, barriers
identified include reluctance to start ART for life and needing time to accept positive test
results before initiating treatment.[17, 19, 30–35] Provider perspectives closely mirrored
accounts from client participants. Similar to our findings, several studies have reported that
the idea of feeling ‘healthy’ was linked to refusing to initiate ART. [18, 34, 36, 37]
Negative attitudes among some HCWs, combined with the lack of privacy at clinics, dis-
tance to access services, and time needed to access HIV care were cited as key barriers to start-
ing ART among clients in our study. Lack of privacy in HIV and ART services has been
associated with individuals avoiding health facilities for fear of inadvertent disclosure to oth-
ers.[17, 31, 33] Poor treatment of HIV-infected clients has been noted in other studies, particu-
larly among pregnant women.[15] It is notable that in our study, there was a mixed experience
with some clients reporting poor treatment at clinics and others specifically raising kindness
and support from HCWs as a facilitator to ART initiation, including variation within a single
clinic. It is likely that chronic shortages in health care workers strain the ability of existing
HCWs to provide compassionate, holistic care.
Our findings also point to the rapid increase in HCWs’ workload as an important consider-
ation as more countries start to implement Test and Treat. The implementation of multi-
month scripting (3- or 6-month scripts) could address this concern by decreasing the number
of clients seen each month.[38, 39] Expanding staffing may also be needed to accommodate
the influx of new clients. Studies have shown the negative impact of an increase in HCWs’
workload without corresponding increase in manpower, particularly in a context with limited
health system infrastructures.[19, 40, 41]
At the community level, some providers and clients suggested that fear of stigma and dis-
crimination affected clients’ health-seeking behaviors. Several studies have described how
anticipated stigma and fear of stigma are associated with non-disclosure and represent impor-
tant barriers to treatment initiation.[17–20, 30–32, 35, 36, 42–45] In addition, religious beliefs
[44] and alternative healing systems or remedies[34, 36] have been reported as barriers to ART
initiation. At least one study identified the concern that ART may affect livelihood if side
effects limit an individual’s ability to carry out daily work.[34] We found that fear of side
effects was a common theme among clients, and individuals who feel healthy have concerns
that starting ART will reduce their quality of life and their ability to carry out daily activities,
including work. Current first-line ART in Mozambique includes the non-nucleoside reverse
transcriptase inhibitor efavirenz (EFV), which is associated with central nervous system (CNS)
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side effects;[46] however, these are typically most pronounced early after initiation and often
improve over time. Education around possible side effects and availability of other ART regi-
mens may reassure patients and help them remain on treatment and/or seek care if they don’t
feel well on first-line EFV. Newer regimens using integrase-inhibitors may eventually replace
EFV with fewer CNS side effects.[47]
Our study found that a few key facilitators positively influenced clients’ willingness to start
and remain in treatment. These included better knowledge about the benefits of ART, the
desire for good health, and the desire to remain healthy to be able to care for dependents. [35]
The desire to appear healthy and avoid the stigma associated with AIDS-related symptoms has
been linked to individuals seeking to test and starting ART in other settings.[37, 48] Other
studies have highlighted that being able to continue to care for family dependents is central to
clients’ decisions to start treatment.[4, 35]
Test and Treat marks a paradigm change from previous strategies addressing the HIV epi-
demic. With the increasing focus on early treatment to optimize long-term health and treat-
ment as prevention, understanding the unique barriers to ART that healthy individuals face is
an important step to ensuring the success of Test and Treat in Mozambique and similar con-
texts. Our data suggest that the following strategies may be helpful optimize treatment uptake
and retention in Test and Treat among healthy clients:
• Individual and group counseling should include messages targeted to clients’ specific needs.
Specific counseling material is needed about the benefits of starting on ART while feeling
healthy and remaining on ART for life, as well as specific strategies healthy clients can use to
overcome barriers to care. Such information may help clients better understand and accept
immediate treatment initiation as part of Test and Treat.
• Community sensitization campaigns are needed to improve client understanding and accep-
tance of immediate treatment initiation under Test and Treat, even before they reach the
health facility. Information on the benefits of treatment for prevention should also be
included. Recent data show understanding treatment as a form of prevention may increase
use of testing and treatment at the community-level.[49]
• Strategies to improve client privacy and decrease wait times should be pursued. Locally-
designed strategies may help manage client flow and reduce wait times in light of increased
demand under Test and Treat. ‘One-stop’ services with integrated HIV/primary care may
also decrease concerns around client privacy and wait times.[50] Client-centered HIV ser-
vices should continue to be pursued as they increase support and improve the over-arching
environment in which care is delivered, potentially improving ART uptake and retention
among healthy clients. Privacy may also be improved through community-based distribu-
tion strategies.
• Multi-month dispensing strategies are needed to accommodate increased demands for ART.
Three-month scripting is well established and successful in other settings.[51, 52] Likewise,
six-month scripting has been validated in other settings[38, 39] and is currently being evalu-
ated in Malawi and Zambia, similar low-resourced settings as Mozambique.[53]
• Additional investments in staffing may be needed to support the increasing number of cli-
ents initiating ART. In particular, there may be a need for additional support staff (counsel-
ors and peer-educators) who can provide additional support to healthy clients initiating
ART under Test and Treat.
The implementation of Test and Treat in Mozambique marks an important paradigm shift
in the enrolment of clients in HIV care, with asymptomatic non-pregnant/breastfeeding adults
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now being offered ART. This study provides novel insights into the way previously established
barriers and facilitators are exacerbated for healthy clients in the context of universal access to
treatment. In order to optimize uptake and retention and achieve the 90/90/90 goals as estab-
lished by UNAIDS, programs will need to address barriers for this population, including
stigma reduction, improved counseling and appropriate education on HIV services, emphasis
on compassionate, client-centered care, and improved privacy and confidentiality at ART clin-
ics. The implementation of the Test and Treat guidelines has generated a rapid increase in the
number of clients enrolled in HIV care, and in the perceived workload of HCWs. New strate-
gies to improve efficiencies and potentially expand the workforce may help to reduce barriers
to care, improve uptake and retention, and optimize long-term outcomes for clients.
Limitations
This study included the perspectives of health providers, as well as men and women who have
both accepted and refused ART as part of the national Test and Treat program; however, there
are several limitations. First, over half of respondents were diagnosed between 3–6 months
prior to completing the in-depth interview. This may create recall bias. However, findings
were similar with clients who were diagnosed recently (<3months), suggesting recall bias is
minimal. Second, the cross-sectional nature of the research design means that we are unable to
confirm that perceived barriers and facilitators predict ART initiation (or not). Finally, repre-
sentation of findings may be limited as only 4 of Mozambique’s 10 provinces were included in
the study, and we excluded provincial and private hospitals, as well as smaller, rural health
facilities, where perspectives of HIV-infected clients and HCWs may be different.
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